Synthesis, Characterization and Antitumor Activity of novel Gold(III) Compounds containing Dithiocarbamates, 2,2'-Bipyridines, and 1,2-Diamminocyclohexane Ligands

The medicinal inorganic chemistry has a significant role in clinical trials for the therapy and diagnosis of various types of cancers. Platinum-based metallodrugs are the major source of chemotherapy for the treatment of different types of cancers, but their successes has been hampered by severe side effects such as nephrotoxicity, lost vision, drug resistance, etc. The recent advancement in the invention of new and unusual gold(III) compounds with square planar structure is leading to the innovation in the field of anticancer drug synthesis and formulation. Gold(III) compounds are emerging effective metal-based materials as alternative potential anticancer agents based on their oxidation state, the coordination geometry, and number as well as the type of coordinated ligands. In the current study, we proposed to synthesize series of novel gold(III) compounds types gold(III)-2,2'-bipyridine with dimethyldithiocarbamate, diethyldithiocarbamate, and dibenzyldithiocarbamate ligands; gold(III)-DACH with some 2,2'-bipyridine derivatives where DACH =1,2-Diaminocyclohexane; gold(III)-pyridine with some DACH ligands. The synthesized complexes will be characterized using FT-IR, 1H, 13C NMR spectroscopy, elemental analyses, and single crystal XRD analysis. Antiproliferative effects of these complexes will be screened against a variety of cancer cell lines and cisplatin-resistance cancer cell lines. The most active complexes will be further tested for their in vivo activity on rats or other suitable animals. The findings of the study will enhance the knowledge and understanding of these complexes and their stability. Also, will help in the development of a new generation of anticancer drugs with fewer side effects than others drugs currently available in the market.